tiprankstipranks
Trending News
More News >
Croda International PLC (GB:50GP)
LSE:50GP
UK Market
Advertisement

Croda International (50GP) AI Stock Analysis

Compare
0 Followers

Top Page

GB:50GP

Croda International

(LSE:50GP)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 4o)
Rating:66Neutral
Price Target:
84.00p
▲(7.69% Upside)
Croda International's overall stock score is driven by its strong financial performance and positive earnings call, which highlight resilience and growth potential. However, technical indicators suggest a lack of momentum, and valuation concerns persist due to the absence of a P/E ratio. The attractive dividend yield partially offsets these risks.

Croda International (50GP) vs. iShares MSCI United Kingdom ETF (EWC)

Croda International Business Overview & Revenue Model

Company DescriptionCroda International Plc creates, makes, and sells specialty chemicals in Europe, the Middle East, Africa, North America, Asia, and Latin America. It operates through four segments: Consumer Care, Life Sciences, Performance Technologies, and Industrial Chemicals. The company offers adhesives; crop protection additives and adjuvants, seed enhancement and animal health chemicals, chemical bio-stimulants, and specialty additives for agricultural films; and lubricant additives, coatings and polymers, vehicle cleaning chemicals, and products for automotive textiles and fibers, as well as specialty additives for plastics, and battery and catalyst industries. It also provides specialty ingredients for self-tanning, color cosmetics, bath and shower, deodorants, anti-perspirants, depilatories, men's grooming, and oral hygiene, as well as skin, hair, sun, body, and baby care applications; construction chemicals and bitumen additives; dietary supplements; and materials and polymer additives for electronics and devices. In addition, the company offers chemistries, emulsifiers, fuel and power generation additives, and polymer additives; food additives; specialty polymer additives for furniture and wood applications; household, industrial, and institutional cleaning products; lubricants; oleochemicals; and packaging, print, and paper chemicals. Further, it provides paints and coatings; active pharmaceutical ingredients; thermal management products; plastic and rubber products; skin health products; hygiene and industrial nonwovens, botanical extracts, tissues, and textile auxiliaries; and water treatment chemicals. Additionally, the company offers bio-based phase change materials for buildings and ventilation, clothing and healthcare, electronics and devices, food and refrigeration, energy storage and recovery, temperature controlled packaging, and vehicles and automotive applications. The company was incorporated in 1925 and is headquartered in Goole, the United Kingdom.
How the Company Makes MoneyCroda International generates revenue primarily through the sale of specialty chemicals and ingredients across multiple sectors. The company operates through several key business divisions, including Personal Care, Crop Care, and Life Sciences, each contributing significantly to its overall revenue. Major revenue streams come from the formulation and distribution of high-value products tailored to meet customer specifications, as well as from long-term contracts with key clients in various industries. Additionally, Croda leverages its commitment to sustainability, which attracts environmentally conscious businesses, thereby enhancing its market position. Strategic partnerships with leading companies in the personal care and agricultural sectors further bolster its earnings by enabling co-development of innovative solutions and expanding market reach.

Croda International Earnings Call Summary

Earnings Call Date:Jul 29, 2025
(Q2-2025)
|
Next Earnings Date:Feb 24, 2026
Earnings Call Sentiment Neutral
The earnings call presented a positive outlook with strong sales growth and significant cost savings initiatives. However, challenges such as political uncertainty in the U.S., higher inventory levels, and price reductions to regain market share were noted.
Q2-2025 Updates
Positive Updates
Sales Growth Across All Segments
Group sales increased by 7% in the first half of the fiscal year, with growth in all three business segments: Consumer Care, Life Sciences, and Industrial Specialties.
Significant Volume Growth
Volumes were up 11%, contributing to an improvement in operating margin from 16.6% to 17.2% year-on-year.
Cost Savings Plan
The company has identified GBP 100 million of annualized cost savings by the end of 2027, up from an initial target of GBP 40 million.
Strong Performance in Europe
Sales in Europe increased by 12%, driven by strong performance in Consumer Care and Life Sciences.
Pharma Sales Growth
Pharma sales grew by 5%, with a focus on improving sales in Consumer Health and veterinary applications.
Negative Updates
Impact of U.S. Political Uncertainty
Political uncertainty in North America led to a decline in consumer confidence, affecting demand in Beauty Actives.
High Inventory Levels
Inventory levels were higher than expected, leading to a working capital outflow of GBP 61 million.
Challenges in the U.S. Pharma Market
Approval processes have slowed, and limited public funding in the U.S. has impacted some areas of the Pharma segment.
Price Reductions to Regain Market Share
Price/mix was 4% lower as the company reduced prices to regain share in certain segments, impacting gross margins.
Company Guidance
During the call, guidance for the fiscal year remained unchanged despite a challenging market environment. The company reported a 7% increase in group sales for the first half of the fiscal year 2025, with sales growth across all three business segments and regions. Adjusted operating profit and profit before tax both increased by 12%, reaching GBP 147 million and GBP 138 million, respectively. The company identified GBP 100 million in annualized cost savings by the end of 2027, up from the previous target of GBP 40 million. The interim dividend was set at 48p, reflecting a slight increase from the prior year. The company also maintained its full-year guidance for adjusted profit before tax of GBP 265 million to GBP 295 million in constant currency, with an anticipated negative currency translation impact of GBP 10 million for the full year.

Croda International Financial Statement Overview

Summary
Croda International shows resilience in a challenging market, maintaining strong margins and a robust balance sheet. While revenue growth has slowed, the company benefits from low leverage and solid equity positions. Cash flows remain stable, though there are signs of pressure on free cash flow. Overall, the company is well-positioned, but mindful management of growth and cash flow is essential moving forward.
Income Statement
62
Positive
The company experienced a decline in revenue from 2022 to 2024, reflecting a challenging market environment. Despite this, margins remain relatively healthy with a gross profit margin of 45.1% and a net profit margin of 9.7% in 2024. The EBIT margin stood at 14.0% and the EBITDA margin at 23.0%, indicating strong operational efficiency despite lower revenues. The declining revenue growth poses a risk to future profitability.
Balance Sheet
75
Positive
The balance sheet is strong with a debt-to-equity ratio of 0.31, suggesting a conservative leverage position. Return on equity was 6.9%, which is moderate. The equity ratio of 65.0% indicates a strong equity buffer and financial stability. The company has managed its liabilities well, maintaining shareholder value and ensuring low leverage risks.
Cash Flow
68
Positive
The cash flow statement reveals stable operating cash flows, though free cash flow decreased from 2022 to 2024, suggesting increased capital investments. The operating cash flow to net income ratio of 2.0 demonstrates effective cash generation from operations. However, the free cash flow to net income ratio dropped to 0.87, indicating pressure on cash available for discretionary use.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.67B1.63B1.69B2.09B1.89B1.39B
Gross Profit614.80M733.90M730.00M864.90M825.60M550.30M
EBITDA355.50M374.50M388.50M924.80M549.40M369.60M
Net Income139.90M158.50M171.00M649.30M320.80M201.60M
Balance Sheet
Total Assets3.46B3.51B3.58B3.61B3.29B3.03B
Cash, Cash Equivalents and Short-Term Investments157.80M166.80M172.50M320.60M112.80M106.50M
Total Debt737.90M699.10M710.10M615.80M936.00M907.00M
Total Liabilities1.23B1.21B1.21B1.18B1.53B1.43B
Stockholders Equity2.22B2.28B2.35B2.42B1.75B1.59B
Cash Flow
Free Cash Flow79.80M137.60M156.80M160.90M190.50M166.30M
Operating Cash Flow226.60M319.40M337.50M313.30M349.20M287.50M
Investing Cash Flow-135.80M-139.10M-409.80M418.10M-218.40M-992.40M
Financing Cash Flow-128.20M-182.60M-52.40M-550.90M-111.90M722.40M

Croda International Technical Analysis

Technical Analysis Sentiment
Negative
Last Price78.00
Price Trends
50DMA
78.00
Positive
100DMA
78.00
Negative
200DMA
79.17
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
0.37
Positive
STOCH
0.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:50GP, the sentiment is Negative. The current price of 78 is below the 20-day moving average (MA) of 78.00, above the 50-day MA of 78.00, and below the 200-day MA of 79.17, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 0.37 is Positive, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:50GP.

Croda International Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
£164.48M15.128.02%3.00%1.12%-0.70%
75
Outperform
£3.47B9.7515.96%3.64%-9.10%239.75%
70
Outperform
£581.00M19.566.65%8.92%4.75%-3.29%
66
Neutral
£3.82B7.11%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
55
Neutral
£934.77M3.37%1.38%-11.78%-92.61%
48
Neutral
£100.59M-7.26%-4.41%2.29%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:50GP
Croda International
78.00
-2.05
-2.56%
GB:ELM
Elementis
163.60
23.62
16.87%
GB:JMAT
Johnson Matthey
2,116.00
701.65
49.61%
GB:SYNT
Synthomer
59.20
-125.00
-67.86%
GB:TET
Treatt plc
279.50
-190.07
-40.48%
GB:VCT
Victrex
643.00
-178.73
-21.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 12, 2025